DAFTAR PUSTAKA

[1] O. Article, N. Fitria, D. Febiana, M. Akram, and R. Yosmar, "narra j Aspirin-clopidogrel combination therapy for ischemic stroke patients : Clinical efficacy and," pp. 1–10, 2024.

[2] S. A. Hartati, "ANALISIS BIAYA TERAPI PASIEN STROKE ISKEMIK PADA INSTALASI RAWAT INAP DI RSUD KOTA MADIUN," vol. 3, pp. 296–303, 2024.

[3] D. Kuriakose, "Pathophysiology and Treatment of Stroke : Present Status and Future Perspectives," 2020.

[4] A. R. W. Maria Helena Elvini Nona Maya, "INTERVENSI TASK ORIENTED APPROACH (TOA) DALAM MENILAI TINGKAT KEKUATAN OTOT PADA PASIEN STROKE NON HEMORAGIK (SNH) DI RUANGAN FLAMBOYAN RSUD DR T.C. HILLERS MAUMERE," vol. 5, pp. 2130–2134, 2024.

[5] T. Dan, K. A. Pada, S. Nurkhalica, A. Fadholah, and S. B. Sawitri, "Jurnal Ilmiah Global Farmasi SINDROM KORONER AKUT DI RSUD DR . MOEWARDI COST-EFFECTIVENESS ANALYSIS OF ASPIRIN MONOTHERAPY AND ASPIRIN-CLOPIDOGREL COMBINATION IN PATIENTS WITH ACUTE CORONARY SYNDROME AT RSUD DR . MOEWARDI," vol. 3, no. 1, pp. 10–20, 2025.

[6] K. M. K. R. INDONESIA and N. HK.01.07/MENKES/394/2019, "PEDOMAN NASIONAL PELAYANAN KEDOKTERAN TATA LAKSANA STROKE," pp. 1–151, 2019.

[7] A. Prodyanatasari *et al.*, *FARMAKOEKONOMI*.

[8] Z.-B. P. Jian-Quan Zhang, "Efficacy and safety of aspirin antiplatelet therapy within 48 h of symptom onset in patients with acute stroke," vol. 11, no. 32, pp. 7814–7822, 2023, doi: 10.12998/wjcc.v11.i32.7814.

[9] M. S. Ummah, "KEPERAWATAN MEDIKAL BEDAH I," *Sustain.*, vol. 11, no. 1, pp. 1–14, 2019.

[10] M. Y. Maretta, D. E. Widyastuti, and A. Apriani, "Preconception Care Practices and Factors Influencing Pregnant Women in Surakarta : A Cross-Sectional Study," vol. 14, no. 1, pp. 14–24, 2026.

[11] R. R. Tjandrawinata, "Peranan Farmakoekonomi dalam Penentuan Kebijakan yang Berkaitan dengan Obat-Obatan," 2016.

[12] M. F. Drummond, "Methods for the Economic Evaluation of Health Care Programmes".

[13] H. Cahyani, A. Ismunandar, T. H. Kartono, R. F. Rosmi, and B. Mulyanto,

"Cost Utility Analysis Penggunaan Obat Combivent Nebulizer dan Ventolin Nebulizer pada Pasien Asma di RSUD Ajibarang Tahun 2024 Cost Utility Analysis of the use of Combivent Nebulizer and Ventolin Nebulizer Drugs in Asthma Patients at Ajibarang Hospital 2024," vol. 5, no. 1, pp. 232–240, 2025.

[14] P. Nerito and A. Sutowijoyo, "Cost Benefit Analysis of Opening Dental Poly Services or Children'S Physiotherapy Poly Services At Safakillah Clinic," *Interdental J. Kedokt. Gigi*, vol. 19, no. 2, pp. 139–147, 2023, doi: 10.46862/interdental.v19i2.7708.

[15] D. A. Listyaningrum and I. K. Permatasari, "Studi Biaya Penggunaan Antibiotik Levofloxacin dan Cefoperazone-Sulbactam pada Pasien Corona Virus Disease-2019 Derajat Ringan sampai Sedang Study of Levofloxacin and Cefoperazone-Sulbactam Utilization Cost on Patients with Mild and Moderate Corona Virus Disease-," vol. 9, no. 1, pp. 59–63, 2024.

[16] A. Nalang, G. Citraningtyas, and W. A. Lolo, "Analisis Efektivitas Biaya (Cost Effectiveness Analysis) Pengobatan Pneumonia Menggunakan Antibiotik," *J. Ilm. Farm.*, vol. 7, no. 3, pp. 321–329, 2018.

[17] D. Handayani and D. Dominica, "Gambaran Drug Related Problems (DRP's) pada Penatalaksanaan Pasien Stroke Hemoragik dan Stroke Non Hemoragik di RSUD Dr M Yunus Bengkulu," vol. 5, no. 1, pp. 36–44, 2018.

[18] D. Cost, "Analisis Perbandingan Biaya Langsung (Direct Cost) dan Biaya Tidak Langsung (Indirect Cost) pada Pasien Stroke Di Rumah Sakit," vol. 2, no. 2014, pp. 82–88, 2017.

[19] N. W. T. I Made Sudarma Adiputra, S. A. M. Ni Putu Wiwik Oktaviani, A. F. Victor Trismanjaya Hulu, Indah Budiastutik, P. O. A. T. Radeny Ramdany, Rosmauli Jerimia Fitriani, S. A. L. Baiq Fitria Rahmiati, and S. Andi Susilawaty, Efendi Sianturi, "Metodologi Penelitian Kesehatan".

[20] D. S. Siyoto, "Dasar Metodologi Penelitian."

[21] I. Agustian, H. E. Saputra, and A. Imanda, "Pengaruh Sistem Informasi Manajamen Terhadap Peningkatan Kualitas Pelayanan Di Pt. Jasaraharja Putra Cabang Bengkulu," *Prof. J. Komun. dan Adm. Publik*, vol. 6, no. 1, pp. 42–60, 2019, doi: 10.37676/professional.v6i1.837.

[22] D. Ernanda, "PENGARUH STORE ATMOSPHERE , HEDONIC MOTIVE DAN SERVICE Sekolah Tinggi Ilmu Ekonomi Indonesia (STIESIA) Surabaya," vol. 6, 2017.

[23] I. M. Inadjo, B. J. Mokalu, and N. Kandowangko, "Adaptasi Sosial SDN 1 Pineleng Menghadapi Dampak Covid-19 Di Desa Pineleng 1 Kecamatan Pineleng Kabupaten Minahasa," *J. Ilm. Soc.*, vol. 3, no. 1, pp. 1–7, 2023.

[24] Riset Kesehatan Dasar (Riskesdas), "Laporan Riskesdas 2018 Nasional.pdf," *Lembaga Penerbit Balitbangkes*. p. hal 156, 2018.

[25] S. Nurkhalica, A. Fadholah, Kurniawan, and S. B. Sawitri, "ANALISIS EFEKTIVITAS BIAYA PENGGUNAAN TERAPI ASPIRIN TUNGGAL DAN KOMBINASI ASPIRIN-CLOPIDOGREL PADA PASIEN SINDROM KORONER AKUT DI RSUD DR. MOEWARDI," *J. Ilm. Glob. Farm.*, vol. 3, no. 1, pp. 10–20, 2025.

[26] E. C. Jauch *et al.*, "Guideline for Healthcare Professionals From the American Heart Association / American AHA / ASA Guideline Guidelines for the Early Management of Patients With Acute Ischemic Stroke A Guideline for Healthcare Professionals From the American Heart Association / American Stroke Association," 2013, doi: 10.1161/STR.0b013e318284056a.

[27] R. Raising and O. Dewi, "ANALISIS KARAKTERISTIK KLINIS dan EFEKTIFITAS TERAPI ANTIPLATELET pada PASIEN STROKE BERULANG di RUMAH SAKIT X," vol. 14, no. 2, 2025.

[28] F. et All., *Global Stroke Fact Sheet 2022 Purpose : Data sources :* 2022.

[29] T. Y. Utomo, "KARAKTERISTIK FAKTOR RISIKO STROKE HEMORAGIK DAN STROKE NON HEMORAGIK DI RSUD KOTA BEKASI," vol. 7, no. 9, 2022.

[30] kemenkes, *Pedoman Penerapan Kajian Farmakoekonomi*. 2013.

[31] S. Octariani, D. Mayasari, and A. M. Ramadhan, "Proceeding of Mulawarman Pharmaceuticals Conferences," pp. 405–412.

[32] N. P. Nasution, D. Wirdatus, S. Harahap, A. Natalia, and B. Ginting, "ANALISIS BIAYA TERAPI ASPIRIN DAN CLOPIDOGREL PADA PASIEN STROKE ISKEMIK DI RUMAH SAKIT ROYAL PRIMA TAHUN 2022 – 2025," vol. 6, no. 1, 2026.

[33] R. Yosmar, D. Febiana, and N. Fitria, "Evaluating Economic Outcomes : Single-Use Aspirin vs . Aspirin-Clopidogrel in Ischemic Stroke Patients Based on Barthel Index Scores," pp. 293–299, 2023, doi: 10.25077/jsfk.10.3.293-299.2023.

[34] M. François P. Sarasin, MD; Jean-Michel Gaspoz, MD, MSc; Henri Bounameaux, "Cost-effectiveness of New Antiplatelet Regimens Used as Secondary Prevention of Stroke or Transient Ischemic Attack," 2000.